Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 1
1994 10
1995 6
1996 4
1997 4
1998 7
1999 2
2000 5
2001 7
2002 4
2003 7
2004 10
2005 5
2006 10
2007 4
2008 5
2009 9
2010 6
2011 6
2012 6
2013 2
2014 5
2015 4
2016 5
2017 3
2018 5
2019 4
2020 5
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

147 results
Results by year
Filters applied: . Clear all
Page 1
Cell signaling by receptor tyrosine kinases.
Lemmon MA, Schlessinger J. Lemmon MA, et al. Cell. 2010 Jun 25;141(7):1117-34. doi: 10.1016/j.cell.2010.06.011. Cell. 2010. PMID: 20602996 Free PMC article. Review.
EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.
Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, Valley CC, Ferguson KM, Leahy DJ, Lidke DS, Lemmon MA. Freed DM, et al. Among authors: lemmon ma. Cell. 2017 Oct 19;171(3):683-695.e18. doi: 10.1016/j.cell.2017.09.017. Epub 2017 Oct 5. Cell. 2017. PMID: 28988771 Free PMC article.
Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.
Sheetz JB, Mathea S, Karvonen H, Malhotra K, Chatterjee D, Niininen W, Perttilä R, Preuss F, Suresh K, Stayrook SE, Tsutsui Y, Radhakrishnan R, Ungureanu D, Knapp S, Lemmon MA. Sheetz JB, et al. Among authors: lemmon ma. Mol Cell. 2020 Aug 6;79(3):390-405.e7. doi: 10.1016/j.molcel.2020.06.018. Epub 2020 Jul 2. Mol Cell. 2020. PMID: 32619402
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, Unni AM, Homer R, Lockwood WW, Michor F, Goldberg SB, Lemmon MA, Smith PD, Cross DAE, Politi K. Starrett JH, et al. Among authors: lemmon ma. Cancer Res. 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819. Epub 2020 Mar 19. Cancer Res. 2020. PMID: 32193290 Free PMC article.
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.
Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. Truini A, et al. Among authors: lemmon ma. Clin Cancer Res. 2019 Nov 1;25(21):6382-6391. doi: 10.1158/1078-0432.CCR-19-0780. Epub 2019 Jun 10. Clin Cancer Res. 2019. PMID: 31182434 Free PMC article.
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. Bresler SC, et al. Among authors: lemmon ma. Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10. Cancer Cell. 2014. PMID: 25517749 Free PMC article.
147 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page